Compare Figs Inc (FIGS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs TransMedics Group Inc — how do they compare? Figs Inc trades at $14.35 (market cap $2.37B), while TransMedics Group Inc trades at $87.25 (market cap $3.10B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and Figs Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| FIGS | TMDX | |
|---|---|---|
Market Cap | $2.37B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $17.12 | $150.42 |
52-Week Low | $6.57 | $61.99 |
Enterprise Value | $2.13B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $14.41, up 0.14% with strong technical momentum as moving averages signal bullish sentiment. The company reported impressive Q2 2026 results with 29% revenue growth and raised full-year guidance, while maintaining robust gross margins of 68.9%. Recent institutional buying and positive analyst coverage support the stock's upward trajectory despite rich valuation multiples.
Outlook remains positive with accelerating revenue growth and margin expansion, though the premium valuation (P/E 43.2) creates high expectations. Key risks include execution challenges in the second half and competitive pressures in healthcare apparel. The consensus price target of $19.50 suggests 35% upside potential from current levels.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
